There is research on this stock available only to PRO subscribers.
Turnaround Strategy Being Implemented At Competitive Technologies
- New CEO brought on board to orchestrate turnaround of ugly historical financial performance.
- First orders of business; new commercialization strategy and cost-control measures.
- Seeking FDA approval of flagship product - will be time consuming/costly but could pay big dividends.
- We think the game plan makes sense but legacy risks remain a big hurdle.
We currently have no Breaking News on this stock.
CTTC vs. ETF Alternatives
Calmare Therapeutics Inc., (CTI) is a biotechnology company developing and commercializing innovative products and technologies. CTI is the licensed distributor of the non-invasive Calmare pain therapy medical device, which incorporates the biophysical Scrambler Therapy technology developed to... More
Other News & PR